Exploring Adults’ Experiences with Tirzepatide for Weight Loss: A Mixed-Methods Study

Изучение опыта взрослых, применяющих тирзепатид для снижения массы тела: исследование с использованием смешанных методов
Shukri Adam, Fatma M. Ibrahim, Eman Abdelaziz Rashad Dabou, Sneha Pitre, Rania Aiman, Shimaa AbdelSamad
2025-11-28

eating self-efficacymixed-methods studypatient-reported outcomestirzepatideweight management
Background: Obesity confers substantial cardiometabolic risk. Tirzepatide, a once-weekly dual GIP/GLP-1 receptor agonist, produces dose-dependent weight loss in trials, but real-world patient-reported experiences are under-described. We evaluated real-world self-efficacy and experiences with tirzepatide in community settings. Methods: Explanatory sequential mixed-methods study of adults aged 18–59 years using tirzepatide for weight management. We collected a quantitative survey (demographics; medication use; 20-item Weight Efficacy Lifestyle Questionnaire [WEL]) followed by purposive semi-structured interviews. Associations between WEL and participant characteristics were tested a priori (two-tailed α = 0.05). Results: Among 120 participants (50.8% male; mean age 42 ± 13 years), 91.7% reported weight loss and 85.8% had <6 months’ exposure. WEL total was 91 ± 34. Higher WEL was observed in females, employed participants, those with insurance coverage versus self-pay, during early months of therapy, and among those with prior weight-loss attempts (all p < 0.05). Interviews (n = 15) indicated high satisfaction, improved sleep/energy, mood, and confidence; gastrointestinal effects were usually mild/transient. Interpretation: In routine care, tirzepatide use was associated with high eating self-efficacy and positive patient-reported outcomes. Variation by coverage and duration suggests value in pairing pharmacotherapy with behavioral support and addressing affordability to sustain benefits.
1
Differences by insurance coverage and treatment duration support combining tirzepatide with behavioral support and addressing affordability to sustain benefits.
2
Higher eating self-efficacy was associated with female sex, employment, insurance coverage, early treatment, and previous weight-loss attempts.
3
In routine community care, 91.7% of 120 adults using tirzepatide for weight management reported weight loss.
4
Interviews revealed high satisfaction and improvements in sleep, energy, mood, and confidence; gastrointestinal effects were generally mild and transient.
5
Participants demonstrated high eating self-efficacy, with a mean Weight Efficacy Lifestyle score of 91 ± 34.

Adults using tirzepatide for weight management in community settings

Real-world eating self-efficacy and patient-reported experiences and outcomes, including satisfaction, well-being, gastrointestinal effects, and variation by insurance coverage and treatment duration

Publication Details
Publication Date
2025-11-28
Journal
Publisher
ISSN
Cited by
4
Access Type
Author Information
Authors
Shukri Adam
Fatma M. Ibrahim
Eman Abdelaziz Rashad Dabou
Sneha Pitre
Rania Aiman
Shimaa AbdelSamad
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%